US Senate committee advances Nicole Saphier as Surgeon General nominee
U.S. Surgeon General nominee Dr. Nicole Saphier testifies before the Senate Health Education, Labor and Pensions Committee on Capitol Hill in Washington, D.C., U.S., September 16, 2026. REUTERS/Evan Vucci
Sept 30 (Reuters) - The US Senate Committee on Health, Education, Labor and Pensions on Wednesday voted to advance Nicole Saphier as the nominee for US Surgeon General.
President Donald Trump nominated Saphier in April, making her his third pick for the post after withdrawing the nominations of Casey Means and, before her, Janette Nesheiwat in May 2025.
• Radiologist Saphier, director of breast imaging at Memorial Sloan Kettering, has a doctor of medicine degree from Ross University School of Medicine, Barbados, and fellowships at the Mayo Clinic
• The former Fox News contributor was grilled earlier this month on childhood vaccines and voiced support for immunization
• The HELP Committee voted to favorably report multiple Trump administration nominees at the Department of Health and Human Services (HHS) and National Mediation Board
• They will face a final Senate vote at a later date
• The committee voted to advance Saphier to be Medical director in the regular corps of the Public Health Service and Surgeon General
• HHS describes the role as the "Nation's Doctor, providing Americans with the best scientific information available on how to improve their health and reduce the risk of illness and injury."
(Reporting by Sneha S K in Bengaluru; Editing by Joyjeet Das)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- House Speaker Johnson says he prefers voluntary AI guardrails ahead of meeting
- US Justice Department files complaint against Minnesota judges who gave interviews about immigration surge
- More than 270 priests in Massachusetts abused children over decades, probe finds
Create E-mail Alert Related Categories
ReutersRelated Entities
Donald J. TrumpSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share